DROLBAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Drolban, and when can generic versions of Drolban launch?
Drolban is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in DROLBAN is dromostanolone propionate. There is one drug master file entry for this compound. Additional details are available on the dromostanolone propionate profile page.
Summary for DROLBAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 50 |
Patent Applications: | 6,435 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DROLBAN at DailyMed |
US Patents and Regulatory Information for DROLBAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | DROLBAN | dromostanolone propionate | INJECTABLE;INJECTION | 012936-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |